News
-
-
-
-
-
PRESS RELEASE
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV received a transparency notification from Atlas Special Opportunities II, LLC indicating a decrease in shareholding below the threshold. The biopharmaceutical company is focused on therapeutic innovation and clinical research technologies -
-
-
-
PRESS RELEASE
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
Valneva SE announces successful outcome of its Annual General Meeting approving 2024 financial statements and appointing Dr. Gerd Zettlmeissl to the Board. Confirms FY 2025 guidance. Shares held steady on Nasdaq & Euronext Paris -